Erasca (NASDAQ:ERAS) Azioni

Erasca

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Erasca Inc

<p>Beauty Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKIN#NASDAQ">SKIN</a>) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Beauty Health to report an <strong>earnings per share</strong> (EPS) of $-0.07.</p>
<p>Beauty Health bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.01, leading to a 5.63% drop in the share price on the subsequent day.</p>
<p>Here's a look at Beauty Health's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.09</td>
<td>-0.12</td>
<td>-0.05</td>
<td>-0.14</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.08</td>
<td>-0.15</td>
<td>-0.10</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>9.0%</td>
<td>-13.0%</td>
<td>-24.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746651821_0.png" alt="eps graph" /></p>
<h3>Market Performance of Beauty Health's Stock</h3>
<p>Shares of Beauty Health were trading at $1.05 as of May 06. Over the last 52-week period, shares are down 60.45%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Insights on Beauty Health</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Beauty Health.</p>
<p>With 2 analyst ratings, Beauty Health has a consensus rating of Neutral. The average one-year price target is $1.38, indicating a potential 31.43% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of FitLife Brands and Medifast, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for FitLife Brands, with an average 1-year price target of $21.0, suggesting a potential 1900.0% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Medifast, with an average 1-year price target of $16.5, suggesting a potential 1471.43% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>In the peer analysis summary, key metrics for FitLife Brands and Medifast are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beauty Health</td>
<td>Neutral</td>
<td>-13.76%</td>
<td>$52.35M</td>
<td>-18.52%</td>
</tr>
<tr>
<td>FitLife Brands</td>
<td>Buy</td>
<td>12.89%</td>
<td>$6.21M</td>
<td>5.89%</td>
</tr>
<tr>
<td>Medifast</td>
<td>Neutral</td>
<td>-33.77%</td>
<td>$84.25M</td>
<td>-0.37%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Beauty Health is at the bottom for Revenue Growth and Gross Profit, with negative values indicating a decline in performance. It is also at the bottom for Return on Equity, showing a negative percentage. Overall, Beauty Health ranks lower compared to its peers in all key metrics, suggesting potential challenges in financial performance.</p>
<h3>All You Need to Know About Beauty Health</h3>
<p>The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.</p>
<h3>Beauty Health: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Beauty Health's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-13.76%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Beauty Health's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-12.37%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Beauty Health's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-18.52%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-1.49%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Beauty Health's debt-to-equity ratio surpasses industry norms, standing at <strong>10.97</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<p><a href="https://www.benzinga.com/quote/SKIN/earnings"><strong>To track all earnings releases for Beauty Health visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

SKIN

Earnings Outlook For Beauty Health

<p>Research Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSSS#NASDAQ">RSSS</a>) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Research Solutions to report an <strong>earnings per share</strong> (EPS) of $0.03.</p>
<p>The announcement from Research Solutions is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.09, leading to a 7.42% drop in the share price on the subsequent day.</p>
<p>Here's a look at Research Solutions's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.02</td>
<td>0.02</td>
<td>-0.06</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.07</td>
<td>0.02</td>
<td>-0.09</td>
<td>0</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>4.0%</td>
<td>1.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746651806_0.png" alt="eps graph" /></p>
<h3>Research Solutions Share Price Analysis</h3>
<p>Shares of Research Solutions were trading at $2.75 as of April 23. Over the last 52-week period, shares are down 1.41%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/RSSS/earnings"><strong>To track all earnings releases for Research Solutions visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


RSSS

A Look at Research Solutions's Upcoming Earnings Report

WIIM

SBGI

Sinclair shares are trading lower after the company reported worse-than-expected Q1 financial results.

<p><strong>Aqua Metals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-08. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Aqua Metals will report an <strong>earnings per share</strong> (EPS) of $-0.60. </p>
<p>Aqua Metals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<p>Here's a look at Aqua Metals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td></td>
<td>-0.80</td>
<td>-1</td>
<td>-1</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.06</td>
<td>-0.76</td>
<td>-1</td>
<td>-1</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-13.0%</td>
<td>-37.0%</td>
<td>9.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Tracking Aqua Metals's Stock Performance</h3>
<p>Shares of Aqua Metals were trading at $1.15 as of May 05. Over the last 52-week period, shares are down 88.32%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/AQMS/earnings"><strong>To track all earnings releases for Aqua Metals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


AQMS

Exploring Aqua Metals's Earnings Expectations

<p>Watts Water Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTS#NYSE">WTS</a>) reported quarterly earnings of $2.37 per share which beat the analyst consensus estimate of $2.12 by 11.79 percent. This is a 1.72 percent increase over earnings of $2.33 per share from the same period last year.  The company reported quarterly sales of $558.00 million which beat the analyst consensus estimate of $547.57 million by 1.90 percent.  This is a 2.26 percent decrease over sales of $570.90 million the same period last year.</p>


Earnings Beats

News

Watts Water Technologies Q1 Adj. EPS $2.37 Beats $2.12 Estimate, Sales $558.00M Beat $547.57M Estimate

<p>Oceaneering International, Inc. ("Oceaneering") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OII#NYSE">OII</a>) announced that its Offshore Projects Group ("OPG") has been awarded a multi-year contract by bp Mauritania Investments Limited for the provision of subsea inspection, maintenance, and repair (IMR) services and remotely operated vehicle (ROV) services in the Greater Tortue Ahmeyim field.</p>
<p>Oceaneering will support this contract with one of its multi-purpose vessels outfitted with two Oceaneering work class ROVs. The scope of work will also include project management, engineering, and integration services provided by Oceaneering's local and international personnel. Engineering and pre-mobilization activities have commenced, with field operations expected to commence in the second quarter of 2025. The initial contract duration is three years, with two one-year options to extend.</p>
<p>Ben Laura, Oceaneering's Chief Operating Officer, stated, "Oceaneering has a track record of safely providing inspection, maintenance, and repair solutions globally. We believe that our expertise in delivering high-quality subsea solutions in harsh environments, utilizing our advanced products and services, was a key element to winning this contract. We look forward to supporting bp's operations in this field."</p>
<p>For more information on Oceaneering's inspection, maintenance, and repair services, please visit: <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.oceaneering.com%2Fimrge-integrated-customizable-imr-solutions%2F&amp;esheet=54250803&amp;newsitemid=20250507264871&amp;lan=en-US&amp;anchor=IMRGE%26%238482%3B+Integrated%2C+Customizable+IMR+Solutions+%7C+Oceaneering&amp;index=1&amp;md5=339face83129f6b95ea192be5b90a169">IMRGE&#x2122; Integrated, Customizable IMR Solutions &#x7C; Oceaneering</a></p>


Contracts

Oceaneering International Announces That Its Offshore Projects Group Has Been Awarded a Multi-Year Contract by BP Mauritania Investments Limited For The Provision Of Subsea Inspection, Maintenance, and Repair Services and Remotely Operated Vehicle Services In The Greater Tortue Ahmeyim Field

<p>Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Co-Diagnostics to report an <strong>earnings per share</strong> (EPS) of $-0.33.</p>
<p>Anticipation surrounds Co-Diagnostics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS missed by $0.02, leading to a 18.26% drop in the share price on the subsequent day.</p>
<p>Here's a look at Co-Diagnostics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.34</td>
<td>-0.33</td>
<td>-0.34</td>
<td>-0.21</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.36</td>
<td>-0.32</td>
<td>-0.25</td>
<td>-0.31</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-18.0%</td>
<td>-3.0%</td>
<td>10.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746651789_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Co-Diagnostics were trading at $0.3495 as of May 02. Over the last 52-week period, shares are down 71.54%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Opinions on Co-Diagnostics</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Co-Diagnostics.</p>
<p>Co-Diagnostics has received a total of 2 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $5.5, the consensus suggests a potential 1473.68% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Ekso Bionics Holdings and Strata Skin Sciences, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Ekso Bionics Holdings, with an average 1-year price target of $4.67, suggesting a potential 1236.19% upside.</li>
<li>Analysts currently favor an Buy trajectory for Strata Skin Sciences, with an average 1-year price target of $6.0, suggesting a potential 1616.74% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Ekso Bionics Holdings and Strata Skin Sciences, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Co-Diagnostics</td>
<td>Buy</td>
<td>-95.80%</td>
<td>$-105.74K</td>
<td>-18.68%</td>
</tr>
<tr>
<td>Ekso Bionics Holdings</td>
<td>Buy</td>
<td>5.01%</td>
<td>$2.71M</td>
<td>-24.75%</td>
</tr>
<tr>
<td>Strata Skin Sciences</td>
<td>Buy</td>
<td>10.21%</td>
<td>$5.76M</td>
<td>-62.83%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Co-Diagnostics ranks at the bottom for Revenue Growth among its peers. It also has the lowest Gross Profit margin. However, it has the highest Return on Equity compared to its peers.</p>
<h3>Unveiling the Story Behind Co-Diagnostics</h3>
<p>Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.</p>
<h3>Co-Diagnostics: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Co-Diagnostics's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-95.8%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Co-Diagnostics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-7387.37%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Co-Diagnostics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-18.68%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-16.18%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Co-Diagnostics's debt-to-equity ratio is below the industry average. With a ratio of <b>0.04</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/CODX/earnings"><strong>To track all earnings releases for Co-Diagnostics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CODX

Examining the Future: Co-Diagnostics's Earnings Outlook

<p><strong>Apple Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares are trading lower Wednesday, under pressure amid a broader shift in the semiconductor supply chain and continued macroeconomic uncertainty<a href="https://www.benzinga.com/25/05/45260942/amd-shifts-chip-orders-to-taiwan-semiconductor-dropping-samsung-in-big-manufacturing-move"> tied to trade and automation.</a></p>
<p><strong>What To Know:</strong> The drop comes as key chipmaker<strong> Advanced Micro Devices Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) ended its 4nm chip production deal with Samsung, citing poor yields and U.S. tariff pressures. AMD has shifted production to <strong>Taiwan Semiconductor Manufacturing Co.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), notably at its Arizona facility, one that Apple and Nvidia have also reportedly turned to in the wake of protectionist trade policies.</p>
<p>AMD&#8217;s strategic migration away from Samsung highlights ongoing vulnerabilities in Apple's supply chain and underscores the geopolitical complexities that tech giants face. Apple has long been a major client of TSMC, and while the move doesn't directly implicate Apple in any supply disruption, it reinforces concerns around cost pressures and manufacturing risks tied to evolving U.S.-Asia trade dynamics.</p>
<p>Additionally, investor sentiment may be reacting to <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45259675/apple-alphabet-shares-tumble-amid-potential-ai-search-shift">news that major tech firms</a>, including Apple, are intensifying their focus on robotics and AI. Amazon's unveiling of its Vulcan warehouse robot and further automation initiatives come as Apple is rumored to be racing Meta in developing AI-powered humanoid robots. While these developments suggest future innovation, they also raise concerns about labor market disruption and regulatory oversight, contributing to sector volatility.</p>
<p><strong>AAPL Price Action</strong>: Apple shares were down 1.89% at $194.80 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a></p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45263291/fed-keeps-rates-steady-warns-of-rising-uncertainty-about-the-economic-outlook">Fed Keeps Rates Steady, Warns Of Rising &#8216;Uncertainty About The Economic Outlook&#8217;</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


Movers

AAPL

Apple Shares Fall Amid Broader Tech Shifts And Supplier Developments: What's Going On?

Earnings Misses

Ferroglobe Q1 Adj. EPS $(0.20) Misses $(0.11) Estimate, Sales $307.20M Miss $336.05M Estimate

<p>Saturn Oil &amp; Gas (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SOIL#TSX">SOIL</a>) reported quarterly earnings of $0.19 per share. This is a 145.24 percent increase over losses of $(0.42) per share from the same period last year.  The company reported $278.08 million in sales this quarter. This is a 65.31 percent increase over sales of $168.22 million the same period last year.</p>


TSX:SOIL

Saturn Oil & Gas Q1 EPS $0.19 Up From $(0.42) YoY, Sales $278.08M Up From $168.22M YoY

SKYT

SkyWater Technology shares are trading lower after the company reported Q1 financial results and issued Q2 guidance below estimates.

<p>Costamare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMRE#NYSE">CMRE</a>) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Costamare to report an <strong>earnings per share</strong> (EPS) of $0.56.</p>
<p>Anticipation surrounds Costamare's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company beat EPS by $0.04, which was followed by a 6.46% drop in the share price the next day.</p>
<p>Here's a look at Costamare's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.65</td>
<td>0.64</td>
<td>0.71</td>
<td>0.65</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.69</td>
<td>0.68</td>
<td>0.77</td>
<td>0.63</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>1.0%</td>
<td>-5.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746651756_0.png" alt="eps graph" /></p>
<h3>Tracking Costamare's Stock Performance</h3>
<p>Shares of Costamare were trading at $6.84 as of May 06. Over the last 52-week period, shares are down 47.51%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CMRE/earnings"><strong>To track all earnings releases for Costamare visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CMRE

An Overview of Costamare's Earnings

<p>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-08. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Prothena Corp to report an <strong>earnings per share</strong> (EPS) of $-1.03.</p>
<p>The announcement from Prothena Corp is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company missed EPS by $0.04, which was followed by a 2.03% increase in the share price the next day.</p>
<p>Here's a look at Prothena Corp's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.04</td>
<td>-1.18</td>
<td>-1.05</td>
<td>-1.20</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.08</td>
<td>-1.10</td>
<td>1.22</td>
<td>-1.34</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-1.0%</td>
<td>4.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746651746_0.png" alt="eps graph" /></p>
<h3>Market Performance of Prothena Corp's Stock</h3>
<p>Shares of Prothena Corp were trading at $7.35 as of May 06. Over the last 52-week period, shares are down 66.86%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Insights on Prothena Corp</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Prothena Corp.</p>
<p>Analysts have provided Prothena Corp with 7 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $58.29, suggesting a potential 693.06% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Regenxbio, Sage Therapeutics and MeiraGTx Hldgs, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Regenxbio, with an average 1-year price target of $32.0, suggesting a potential 335.37% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Sage Therapeutics, with an average 1-year price target of $9.5, suggesting a potential 29.25% upside.</li>
<li>Analysts currently favor an Buy trajectory for MeiraGTx Hldgs, with an average 1-year price target of $24.5, suggesting a potential 233.33% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>Within the peer analysis summary, vital metrics for Regenxbio, Sage Therapeutics and MeiraGTx Hldgs are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Precigen</td>
<td>Buy</td>
<td>-3.09%</td>
<td>$21K</td>
<td>-42.02%</td>
</tr>
<tr>
<td>Regenxbio</td>
<td>Buy</td>
<td>-4.50%</td>
<td>$14.90M</td>
<td>-18.25%</td>
</tr>
<tr>
<td>Sage Therapeutics</td>
<td>Neutral</td>
<td>77.97%</td>
<td>$13.41M</td>
<td>-14.22%</td>
</tr>
<tr>
<td>MeiraGTx Hldgs</td>
<td>Buy</td>
<td>948.53%</td>
<td>$9.58M</td>
<td>-48.18%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Prothena Corp ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, Prothena Corp is at the bottom compared to its peers.</p>
<h3>Unveiling the Story Behind Prothena Corp</h3>
<p>Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.</p>
<h3>Prothena Corp's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Prothena Corp displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>571.84%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Prothena Corp's net margin is impressive, surpassing industry averages. With a net margin of <strong>-2729.91%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Prothena Corp's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-11.35%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-10.15%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Prothena Corp's debt-to-equity ratio is below the industry average at <strong>0.02</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/PRTA/earnings"><strong>To track all earnings releases for Prothena Corp visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PRTA

A Look Ahead: Prothena Corp's Earnings Forecast

<p>NN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNBR#NASDAQ">NNBR</a>) lowers FY2025 sales outlook from $650.00 million to $430.00 million-$460.00 million vs $458.93 million estimate.</p>


Guidance

NNBR

NN Lowers FY2025 Sales Guidance from $650.00M to $430.00M-$460.00M vs $458.93M Est

Buybacks

STKL

SunOpta Announces Share Repurchase Authorization Of Up To $25M

CENX

Century Aluminum shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results.

<p><strong>Perimeter Solutions</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRM#NYSE">PRM</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-08. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Perimeter Solutions will report an <strong>earnings per share</strong> (EPS) of $0.01. </p>
<p>Anticipation surrounds Perimeter Solutions's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.19, leading to a 7.58% drop in the share price the following trading session.</p>
<p>Here's a look at Perimeter Solutions's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.06</td>
<td>0.62</td>
<td>0.01</td>
<td>-0.13</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.13</td>
<td>-0.61</td>
<td>0.14</td>
<td>-0.57</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-8.0%</td>
<td>-1.0%</td>
<td>-10.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746651732_0.png" alt="eps graph" /></p>
<h3>Perimeter Solutions Share Price Analysis</h3>
<p>Shares of Perimeter Solutions were trading at $10.52 as of May 06. Over the last 52-week period, shares are up 38.14%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on Perimeter Solutions</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Perimeter Solutions.</p>
<p>The consensus rating for Perimeter Solutions is Buy, derived from 1 analyst ratings. An average one-year price target of $14.0 implies a potential 33.08% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Ingevity, Minerals Technologies and Quaker Houghton, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Ingevity, with an average 1-year price target of $49.25, suggesting a potential 368.16% upside.</li>
<li>Analysts currently favor an Buy trajectory for Minerals Technologies, with an average 1-year price target of $89.0, suggesting a potential 746.01% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Quaker Houghton, with an average 1-year price target of $147.25, suggesting a potential 1299.71% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for Ingevity, Minerals Technologies and Quaker Houghton, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perimeter Solutions</td>
<td>Buy</td>
<td>45.04%</td>
<td>$41.90M</td>
<td>13.36%</td>
</tr>
<tr>
<td>Ingevity</td>
<td>Neutral</td>
<td>-4.95%</td>
<td>$101.90M</td>
<td>9.54%</td>
</tr>
<tr>
<td>Minerals Technologies</td>
<td>Buy</td>
<td>-7.99%</td>
<td>$119.60M</td>
<td>-8.61%</td>
</tr>
<tr>
<td>Quaker Houghton</td>
<td>Neutral</td>
<td>-5.71%</td>
<td>$161.26M</td>
<td>0.94%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Perimeter Solutions ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the lowest Return on Equity.</p>
<h3>About Perimeter Solutions</h3>
<p>Perimeter Solutions Inc is a solutions provider for the Fire Safety and Specialty Products industries. The Company's products and operations are managed and reported in two operating segments. Its Fire Safety segment provides fire retardants and firefighting foams, as well as specialized equipment and services typically offered in conjunction with the Company's retardant and foam products. The Specialty Products segment includes operations that develop, produce and market products for non-fire safety markets. Specialty Products segment is Phosphorus Pentasulfide (P2S5) based lubricant additives. P2S5 is also used in pesticide and mining chemicals applications, and emerging electric battery technologies.</p>
<h3>Perimeter Solutions: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Perimeter Solutions's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>45.04%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Materials sector.</p>
<p><strong>Net Margin:</strong> Perimeter Solutions's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>167.19%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>13.36%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Perimeter Solutions's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>5.91%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Perimeter Solutions's debt-to-equity ratio is below the industry average at <strong>0.6</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/PRM/earnings"><strong>To track all earnings releases for Perimeter Solutions visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Glimpse of Perimeter Solutions's Earnings Potential

<p>Stabilis Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNG#NASDAQ">SLNG</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.03) by 200 percent. This is a 212.5 percent decrease over earnings of $0.08 per share from the same period last year.  The company reported quarterly sales of $17.34 million which missed the analyst consensus estimate of $19.80 million by 12.43 percent.  This is a 12.30 percent decrease over sales of $19.77 million the same period last year.</p>


SLNG

Stabilis Solutions Q1 EPS $(0.09) Misses $(0.03) Estimate, Sales $17.34M Miss $19.80M Estimate

<p>Sphere Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-08. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Sphere Entertainment to report an <strong>earnings per share</strong> (EPS) of $-2.14.</p>
<p>The announcement from Sphere Entertainment is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $1.06, leading to a 0.37% drop in the share price on the subsequent day.</p>
<p>Here's a look at Sphere Entertainment's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-2.43</td>
<td>-2.76</td>
<td>-2.04</td>
<td>-0.19</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-3.49</td>
<td>-2.95</td>
<td>-2</td>
<td>-1.33</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-0.0%</td>
<td>2.0%</td>
<td>4.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746651712_0.png" alt="eps graph" /></p>
<h3>Sphere Entertainment Share Price Analysis</h3>
<p>Shares of Sphere Entertainment were trading at $28.99 as of May 06. Over the last 52-week period, shares are down 27.82%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SPHR/earnings"><strong>To track all earnings releases for Sphere Entertainment visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SPHR

What to Expect from Sphere Entertainment's Earnings

ASLE

AerSale shares are trading lower after the company reported worse-than-expected Q1 sales results.

Press Releases

Erasca to Present at Upcoming Investor Conferences

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

Clear Street Launches Healthcare & Biotechnology Equity Research

Small Cap

Opinion

Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

Health Care

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

General

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

Comments

Erasca

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO